- Worldwide Delivery4-7 business days
- Quality GuaranteedOnly original products
- Bonus pillsSave up to 80%
- 24/7 SupportOur team of pharmacists is available 24/7 to help you
Adults diagnosed with schizophrenia or bipolar I disorder may be prescribed Olanzapine to reduce psychosis, agitation and manic symptoms. It is an atypical antipsychotic that regulates dopamine and serotonin signalling in the brain. Treatment is individually adjusted because benefits and adverse effects differ between patients.
Product information
Olanzapine is an atypical antipsychotic. Its active ingredient is olanzapine, which regulates dopamine and serotonin signalling in the brain.
How it affects the body
Olanzapine is a dopamine receptor antagonist and a serotonin receptor antagonist. A receptor antagonist reduces the activation of a receptor by blocking or limiting the effect of a signalling chemical.
Dopamine receptor antagonism
Excessive dopamine activity in some brain pathways contributes to hallucinations, delusions and disorganised thinking. By reducing dopamine receptor signalling, olanzapine can lessen these positive symptoms of schizophrenia and help reduce manic activation.
This action does not predict exactly how one person will respond. Dopamine pathways also influence movement, motivation and alertness, so treatment can produce sleepiness, slowed reactions or other neurological effects.
Serotonin receptor antagonism
Olanzapine also affects serotonin receptors. Serotonin receptor antagonism contributes to its broader antipsychotic profile and may influence mood, anxiety, appetite and sleep.
The same receptor activity creates a clinical trade-off. Olanzapine can reduce severe psychotic or manic symptoms, yet it can also increase appetite, drowsiness and metabolic risk. The European Medicines Agency describes these effects within the medicine’s established safety profile [2].
Ingredients
The treatment is intended for clinically diagnosed conditions rather than ordinary sadness, everyday stress or uncomplicated anxiety. A prescriber may use it for schizophrenia, bipolar I disorder and selected specialist treatment plans. The FDA prescribing information describes olanzapine as an antipsychotic for schizophrenia and bipolar mania, with treatment decisions based on the patient’s symptoms, medical history and response [1].
Active ingredient and therapeutic class
Olanzapine belongs to the antipsychotic class. It acts on several neurotransmitter receptors, which explains both its therapeutic effects and some of its tolerability limitations.
The main clinical goals include:
- reducing hallucinations, delusions and disorganised thinking;
- calming severe agitation linked to psychosis or mania;
- reducing manic activation in bipolar I disorder;
- supporting longer-term mood and symptom stability when continued treatment is appropriate;
- assisting specialist treatment plans for treatment-resistant depression when combined with another antidepressant.
Response varies. One patient may notice calmer thoughts first, while another may experience early sleepiness before clearer improvement in psychotic or mood symptoms.
Dosage and administration
The dose is decided individually, taking age, other medicines and health conditions into account. Schizophrenia and bipolar disorder do not have one universal starting dose for every adult.
- Take the tablets exactly as prescribed, at the prescribed time.
- Swallow the tablet with water unless the prescriber has given different instructions.
- Take it consistently, with or without food if that is how it was prescribed.
- Do not change the dose because symptoms improve or sleepiness becomes inconvenient.
- If a dose is missed, take it when remembered unless the next dose is near; never take two doses together.
- Store the tablets in a dry place away from children and excessive heat.
- Avoid driving, climbing or hazardous work until the effect on alertness is known.
A lower starting approach may be selected for older adults or people with medical vulnerability. Dose changes can also be needed when interacting medicines are started or stopped.
When this is not for you
Olanzapine is NOT for you if a prescriber determines that its risks outweigh likely benefits or if required monitoring cannot be completed.
Olanzapine requires careful review in people with diabetes, cardiovascular disease, seizure disorders, dehydration risk or a history of falls. Older adults may experience more dizziness, confusion or postural blood-pressure changes, so slower adjustments and closer follow-up may be appropriate.
Possible side effects
Common adverse effects include drowsiness, increased appetite, weight gain, constipation, dry mouth, dizziness and postural light-headedness. The FDA label identifies weight and metabolic effects as important parts of olanzapine safety monitoring .
Drowsiness and reduced alertness
Drowsiness can affect concentration, reaction time and balance. Alcohol, sleeping tablets, opioid pain medicines and sedating antihistamines may intensify this effect.
Do not stop olanzapine suddenly without a prescriber’s plan. Abrupt changes can cause insomnia, nausea, restlessness or return of psychotic or mood symptoms.
Appetite, weight and metabolic effects
Appetite can increase before weight changes become obvious. Early weight tracking is useful because it allows the treatment plan to be reviewed before a larger change develops.
Practical measures include regular meals, limiting energy-dense snacks and maintaining physical activity appropriate to health status. Weight gain is not a personal failure; it can reflect the medicine’s effect on appetite and metabolism. Rapid weight gain, marked thirst, frequent urination or unusual fatigue require prompt clinical review.
Constipation deserves attention too. Adequate fluids, fibre and movement may help when medically appropriate, while severe abdominal pain, vomiting or inability to pass stool needs urgent assessment.
Therapeutic indications
Olanzapine is used mainly for schizophrenia and bipolar I disorder. Treatment-resistant depression is a specialist-directed use that may involve olanzapine with an antidepressant after inadequate response to previous treatment.
| Clinical condition | Main treatment goal | Specialist consideration |
|---|---|---|
| Schizophrenia | Reduce psychosis and disorganisation | Ongoing symptom and metabolic review |
| Bipolar I disorder | Control manic episodes and support mood stability | Treatment plan depends on current and past mood episodes |
| Treatment-resistant depression | Augment another antidepressant in selected cases | Requires specialist assessment and monitoring |
Schizophrenia symptom control
Schizophrenia may involve hallucinations, delusions, disorganised speech, social withdrawal and impaired functioning. Olanzapine can reduce psychotic symptoms, but it does not remove the underlying vulnerability permanently. Continued treatment decisions depend on relapse history, response, adverse effects and the patient’s preferences.
Early calming can occur before the full antipsychotic benefit becomes clear. A person may sleep more during the first days while hallucinations or fixed beliefs take longer to improve.
Bipolar I mania and mood stabilisation
During mania, a person may have unusually high energy, little need for sleep, rapid speech, impulsive decisions, irritability or agitation. Olanzapine can help reduce manic activation and agitation. The treatment plan may also involve a mood stabiliser such as valproate or lithium under specialist supervision.
Mood improvement does not mean that bipolar I disorder has resolved. Stopping treatment when sleep returns can allow symptoms to rebuild.
Specialist use in treatment-resistant depression
Some specialist treatment plans use olanzapine alongside an antidepressant for treatment-resistant depression. This approach is different from using olanzapine for ordinary low mood. The prescriber must weigh expected benefit against sedation, appetite increase, weight gain and metabolic changes.
Comparison
Olanzapine, risperidone and aripiprazole are atypical antipsychotics, but their receptor effects and tolerability profiles differ.
| Medicine | Common clinical trade-off | Monitoring focus |
|---|---|---|
| Olanzapine | Strong antipsychotic and antimanic activity, with greater appetite, weight and metabolic concerns in many patients | Weight, glucose, cholesterol and sedation |
| Risperidone | May cause prolactin-related effects and movement symptoms at higher exposure | Prolactin symptoms, movement changes and metabolic health |
| Aripiprazole | Often less sedating and less associated with weight gain, but akathisia can occur | Restlessness, insomnia, movement symptoms and response |
No antipsychotic is the best choice for every patient. The decision depends on previous response, symptom pattern, diabetes risk, cardiovascular history, sleep needs and the patient’s tolerance of sedation or restlessness.
Olanzapine may be selected when control of psychosis or mania is the priority. Its limitation is the need for close attention to appetite, weight and metabolic changes.
Common mistakes
Several habits can reduce treatment benefit or increase risk:
- stopping when hallucinations or manic symptoms improve;
- doubling the next dose after a missed tablet;
- adding a sleeping medicine or sedating antihistamine without checking interactions;
- treating increased appetite as harmless until substantial weight gain appears;
- failing to report a major smoking change;
- driving before the effect on alertness is known;
- assuming that a new prescription cannot interact with olanzapine;
- ignoring repetitive facial or tongue movements;
- stopping suddenly after several months of treatment.
Symptom improvement does not prove that the underlying condition has resolved. Treatment changes should be planned with the prescriber.
What doctors say
In clinical practice, prescribers often look for a steady reduction in agitation, sleeplessness, hallucinations or disorganised thinking rather than an immediate total change. Early sedation can show that the medicine is affecting the nervous system, but it does not by itself prove that the long-term treatment plan is right.
Doctors also monitor physical health alongside psychiatric symptoms. A patient can feel mentally better while blood glucose, cholesterol or weight are changing. The EMA and WHO support combining symptom review with physical-health assessment during antipsychotic treatment [2,3].
A practical clinical rule is to report new symptoms early. New involuntary movements, severe constipation, fainting, rapid weight change or intense daytime sedation should not wait for a routine medication renewal.
Common questions
Which symptoms mean stopping Olanzapine and seeking urgent medical help?
High fever, severe muscle stiffness, confusion, heavy sweating, seizures, fainting, breathing difficulty, throat swelling or severe uncontrolled movements require urgent medical assessment. These symptoms may indicate neuroleptic malignant syndrome, a serious allergic reaction, cardiovascular complications or another emergency. The FDA's 2024 safety information identifies these reactions as requiring prompt attention. Do not wait for the next routine appointment, and do not drive yourself if you are confused, faint or severely unwell.
How long can an Olanzapine treatment course last, and is long-term use acceptable?
The course may be short-term, maintenance-based or long-term, depending on schizophrenia, bipolar I disorder, relapse risk and treatment response. Long-term use can be appropriate when benefits continue to outweigh adverse effects, with regular physical and psychiatric monitoring. NICE's 2014 guidance supports ongoing review of antipsychotic treatment and physical health rather than automatic continuation or automatic stopping [3]. Never shorten a long-term treatment plan solely because symptoms have improved. Follow-up should reassess symptoms, adverse effects and physical-health measures.
What should be discussed with a doctor before starting Olanzapine?
Discuss diabetes risk, cholesterol, heart disease, fainting, seizures, liver problems, pregnancy, breastfeeding, smoking and every medicine or supplement being used. Mention alcohol intake and any history of severe constipation or falls. The EMA's 2023 product information highlights the relevance of metabolic, neurological and cardiovascular factors when olanzapine is prescribed. These details help determine monitoring needs and whether another treatment approach may be more suitable.
Can Olanzapine tablets be split, crushed or chewed?
Do not split, crush or chew the tablets unless the prescriber or dispensing pharmacist has specifically confirmed that this is suitable for the supplied formulation. Altering a tablet can affect accurate dosing, swallowing and tolerability. The FDA's 2024 prescribing information describes administration of olanzapine tablets according to the prescribed regimen. If swallowing is difficult, report it before changing the tablet yourself.
Does Olanzapine cause weight gain?
Olanzapine can increase appetite and may cause weight gain, with metabolic changes involving blood glucose or cholesterol in some patients. The effect varies, and early monitoring can identify a problem before it becomes substantial. WHO's 2016 guidance supports routine physical-health checks for people receiving antipsychotic treatment. Rapid weight change, excessive thirst or frequent urination should prompt a clinical review.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Comparison
Sources
- U.S. Food and Drug Administration (2024). ZYPREXA (olanzapine) Prescribing Information.
- European Medicines Agency (2023). Summary of Product Characteristics (SmPC) — olanzapine.
- National Institute for Health and Care Excellence (2014). Psychosis and schizophrenia in adults: prevention and management.